Search for: "Astrazeneca"
Results 1061 - 1080
of 1,246
Sorted by Relevance
|
Sort by Date
29 Jun 2006, 5:04 pm
Goddard told Reuters Health that in its failed trial, AstraZeneca was using doses of Iressa one-third to two-thirds of the maximum tolerable dose. [read post]
8 Dec 2007, 11:00 am
: (IP Think Tank), WIPO - Idris gets paid out to leave early: (IAM), (Patent Prospector), Deutsche Grammophon ditches DRM: (ArsTechnica)PharmaFDA revisits NCE exclusivity for enantiomers: (Arnall Golden & Gregory), Accupril (Quinapril) - Judge finds against Teva and holds Warner-Lambert patent enabled: (IPLaw360), (OrangeBookBlog), Altace / Tritace / Ramace (Ramipril) - King Pharmaceuticals loses CAFC rehearing bid: (IPLaw360), … [read post]
6 May 2017, 10:11 am
The decision Braintree v. [read post]
10 Aug 2017, 3:41 pm
. | Changes to the Singapore copyright system: an update on the recent public consultations | he diplomatic crisis of Qatar and Gulf Cooperation Council's IP | Bundesgerichtshof's landmark ruling to hook extra-territorial patent infringement in Germany | BREAKING: Eli Lilly success as UK Supreme Court finds Actavis products directly and indirectly infringe pemetrexed patent | Monday Miscellany | Sunday SurprisesNever Too Late 154 [week ending Sunday 2 July] I Book Review: Patent Drawing… [read post]
18 Dec 2015, 9:19 am
AstraZeneca Pharm. [read post]
2 Apr 2016, 12:20 pm
" Nicholas also raised Astrazeneca v Apotex where the Federal Circuit relied in part on a settlement agreement entered into after the patent had been found valid an infringed to calculate damages. [read post]
8 Sep 2014, 4:55 am
.* The skilled person - more knowledgeable than ever beforeDavid covers the exciting pharma-patent ruling in Teva UK Limited & another v AstraZeneca AB [2014] EWHC 2873 (Pat) by Mr Justice Sales in the Patents Court for England and Wales, which focuses on the concept of Common General Knowledge (CGK). [read post]
23 Sep 2016, 7:12 am
See AstraZeneca AB v. [read post]
25 Feb 2013, 2:39 pm
AstraZeneca Pharma., 2009 U.S. [read post]
22 Jun 2015, 9:24 am
******************PREVIOUSLY, ON NEVER TOO LATE Never too late 50 [week ending on Sunday 7 June] - Swiss claims | Italian-sounding trade marks for cosmetics | “IP litigation and Enforcement” event | Saving WiFi | Spy scandal at the EPO | Rihanna v DC Comics | KitKat trade mark | Taste trade marks in the Netherlands | Connectivity and human rights | Trade secrets, client confidentiality and privilege | 3-d printing and counterfeiting | Ericsson v Apple in the… [read post]
31 Jan 2023, 10:19 am
Although Merpel wonders why the offers were not also made under Part 36, the Judge nevertheless decided that the refusal of the offers by ONI was not "highly unreasonable" (as is the test under see White Book CPR 44.3.12, F & C Alternative Investments (Holdings) v Barthelemy [2012] EWCA Civ 843 at [70] (citing Kiam v MGM), Astex Therapeutics v AstraZeneca [2018] EWCA Civ 2444 at [61]-[78]). [read post]
9 Sep 2020, 12:19 pm
The drugmaker AstraZeneca, which is running the trial with Oxford University, has refused to explain the nature of the patient’s illness, and it is now reviewing whether the incident was caused by the vaccine or happened by chance. [read post]
25 May 2015, 4:15 am
, Paul Inman and Ailsa Carter, have summarised last week's decision from the Court of Appeal in AstraZeneca AB & Another v KRKA dd Novo Mesto & Another [2015] EWCA Civ 484.* F1 ends up in hot water - no similarity to F1H2OIn Case T-55/13 the General Court of the European Union deals with Formula One Licensing BV's opposition against Idea Marketing SA’s Community trade mark application for 'F1H2O'. [read post]
16 Aug 2024, 9:15 am
This week in Other Barks & Bites: The U.S. [read post]
16 Aug 2024, 9:15 am
This week in Other Barks & Bites: The U.S. [read post]
31 Mar 2016, 6:40 am
" Dr Peters, who also writes a column for Medscape Diabetes & Endocrinology, has served as a speaker or consultant with Eli Lilly, Boehringer Ingelheim Pharmaceuticals, and AstraZeneca Pharmaceuticals, which make SGLT-2 inhibitors. [read post]
26 Jun 2007, 7:00 am
AstraZeneca Pharmaceuticals, L.P., Case No. 3:07-cv-02313-FLW-TJB (D.N.J. filed May 16, 2007) (asserting claims associated with alleged off-label promotion).Given the variety of claims asserted, they are subject to a wide range of defenses. [read post]
14 Apr 2021, 6:49 am
A proposal which follows a Report from the De Boufflers Institute (May 2020) and a Collective Tribune bringing together renowned specialists in property and patent laws (academics and practitioners), who invite the French public authorities to reform the compulsory licensing procedure and to engage it to facilitate the manufacturing of Covid-19 vaccines in France (March 2021). [2] https://www.citizen.org/article/biontech-and-pfizers-bnt162-vaccine-patent-landscape/ [3]… [read post]
18 Oct 2011, 9:33 am
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352 (11th Cir. 2011)? [read post]
15 Dec 2010, 2:17 am
Becton, Dickinson & Co (Intellectual Property Law Blog) US: Regents of the University of California pursue new patent re-examination in District Court (Patents Post Grant Blog) US: Microsoft v i4i, the burden of proof and the pharma sector (PatLit) US: IRS issues notice to implement annual fee on brand drugs (FDA Law Blog) US: Bright ‘orphan’ ideas blossom (FDA Law Blog) US: Amicus briefs in AMP v USPTO (Patent Docs) (Patent Docs) (Patent Docs) US: University of California files for… [read post]
